The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, ...
Phosphatidylinositol 3-kinase (PI 3K) acts upstream of myriad cellular pathways, including those that regulate protein synthesis and tumorigenesis. In this example, PI 3K phosphorylates the lipid PI ...
As previously presented, gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet”) and gedatolisib + fulvestrant ('gedatolisib doublet”) reduced the risk of disease progression or death versus ...
A systematic review to assess the efficacy of HER2-targeted treatment regimens in HER2-positive metastatic colorectal cancer (mCRC). This is an ASCO Meeting Abstract from the 2023 ASCO ...
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study A total of 3.4% (41/1,206) of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results